1 |
CHEN W Q,ZHENG R S, BAADE P D,et al.Cancer statistics in China, 2015[J].CA Cancer J Clin,2016,66(2) : 115-132.
|
2 |
王丽萍.非小细胞肺癌的靶向和免疫治疗进展[J].郑州大学学报(医学版),2020,55(2):176-182.
|
3 |
王 辉,初向阳,王 波,等.原发性肺腺癌间质上皮转化因子mRNA 的表达及意义[J]. 解放军医学院学报,2015,36(7):661-667.
|
4 |
AUTOR C A, ROMERO A, JUAN V C D, et al. EP1.14-11 real-life data of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation[J]. J Thorac Oncol, 2019,14(10):S1036.
|
5 |
ONITSUKA T, URAMOTO H, NOSE N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status[J]. Lung Cancer, 2010, 68(2):198-203.
|
6 |
周 娟. T790M及EMT在预测EGFR-TKI继发耐药后化疗疗效中的重要作用及机制[D]. 上海:第二军医大学,2016.
|
7 |
DENIS M G, VALLEE A, THEOLEYRE S. EGFR T790M resistance mutation in non small-cell lung carcinoma[J]. Clin Chimica Acta,2015,444:81-85.
|
8 |
潘亚强,李振华,李定彪.表皮生长因子受体突变非小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂继发性耐药机制及靶向治疗新策略的研究进展[J].实用心脑肺血管病杂志,2019,27(12):21-27.
|
9 |
PARDOLL D M. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264.
|
10 |
马 薇, 罗殿中, 陈 源, 等. PD-L1和PD-1在非小细胞肺癌中的表达及其临床意义[J]. 实用医学杂志, 2011, 27(9):1551-1554.
|
11 |
韩丽芳, 王 珍, 关 颖. PD-1和PD-L1在结直肠癌中的表达及其临床病理意义[J]. 医药前沿, 2019,9(28):18-20.
|
12 |
VELCHETI V, SCHALPER K A, CARVAJAL D E, et al. Programmed death ligand-1 expression in non-small cell lung cancer[J]. Lab Investig J Tech Methods Pathol, 2014, 94(1): 107-116.
|
13 |
林喜娜, 李广秋, 何 萍,等. 非小细胞肺癌中PD-L1表达及其与肺癌相关驱动基因的关系[J]. 临床与实验病理学杂志, 2019,35(7):767-771.
|
14 |
AZUMA K, OTA K,KAWAHRA A,et al.Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer[J].Ann Oncol,2014,25(10):1935-1940.
|
15 |
孙 瑾,张俊卿,黄延林,等.CRISPR/Cas9建立IL-12 p35基因敲除大鼠C6细胞系表达研究[J].中国免疫学杂志,2019,35(20):2452-2456.
|
16 |
WANG N, ZHANG T I. Downregulation of microRNA-135 promotes sensitivity of non-small cell lung cancer to gefitinib by targeting TRIM16[J]. Oncol Res, 2018, 26(7):1005-1014.
|
17 |
谢刚强, 刘春田, 张永庆, 等. 吉非替尼治疗非小细胞肺癌患者的临床疗效分析 [J]. 现代生物医学进展, 2016,16(34):6754-6757.
|
18 |
ZENG L, XIAO L, JIANG W,et al. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population[J]. Lung Cancer,2020,141:82-88.
|
19 |
于 芹,姜 达,李 颖.T790M突变的非小细胞肺癌研究现状与前景[J].中国肺癌杂志,2017,20(3):199-204.
|
20 |
HAN J J, KIM D W, KOH J, et al. Change in PD-L1 expression after acquiring resistance to gefitinib in EGFR-mutant non-small-cell lung cancer[J]. Clin Lung Cancer, 2016, 17(4):263-270.e2.
|
21 |
熊 伟,杨勇琴,自加吉,等.CRISPR-Cas9基因编辑技术在构建实验动物肿瘤模型中的应用进展[J].生物技术通讯,2017,28(4):551-557.
|
22 |
陈 晨. 利用CRISPR/Cas9文库在非小细胞肺癌中对奥西替尼耐药基因的筛选与鉴定研究[D].洛阳:河南科技大学,2019.
|
23 |
彭顺利. EGFR-TKIs耐药通过上调肺癌PD-L1的表达促进肿瘤免疫逃逸的研究[D].广州:南方医科大学,2017.
|